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Abstract
Genetic factors associated with the risk of smoking related cancers have until recently remained elusive. Since the
publication of a genome-wide association study (GWAS) on lung cancer new genetic loci have been identified that appear
to be associated with disease risk. In this replication study we genotyped 14 single nucleotide polymorphisms (SNPs)
located at the 5p12.3-p15.33, 6p21.3-p22.1, 6q23-q27 and 15q25.1 loci in 874 lung, 450 bladder, 418 laryngeal cancer cases
and cancer-free controls, matched by year of birth and sex to the cases. Our results revealed that loci in the chromosome
region 15q25.1 (rs16969968[A], rs8034191[G]) and 5p15 (rs402710[T]) are associated with lung cancer risk in the Polish
population (smoking status adjusted OR=1.45, 1.35, 0.77; p#0.0001, 0.0005, 0.002; 95%CI 1.23–1.72, 1.14–1.59, 0.66–0.91
respectively). None of the other regions analyzed herein were implicated in the risk of lung, bladder or laryngeal cancer. This
study supports previous findings on lung cancer but fails to show association of SNPs located in 15q25.1 and 5p15 region
with other smoking related cancers like bladder and laryngeal cancer.
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Introduction
Lung cancer remains the leading cause of cancer death. Every
year more than 1 million new cases are diagnosed and a significant
proportion die within two years of diagnosis [1]. Tobacco smoking
is the major risk factor for lung cancer, but there is a distinct group
of patients who develop the disease without a history of tobacco
smoking. Furthermore, there are reports suggesting that a positive
family history of lung cancer is an important risk factor for this
disease [2].
Despite a large number of studies aimed at identifying genetic
factors that modify lung cancer risk, no clear picture has emerged.
In 2008 genome wide association studies (GWAS) revealed a series
of single-nucleotide polymorphisms (SNPs) occurring at distinct
loci, strongly associated with various aspects of disease risk. A locus
at chromosome 15q25.1 was associated with lung cancer risk [3–
9], nicotine and alcohol dependence [10–14]. Polymorphic
markers of this particular region were located in the region of
the nicotinic acetylcholine receptor gene CHRNA5, CHRNA3 and
the aminoglycoside phosphotransferase domain containing 1 gene
AGPHD1. There is also evidence that other loci are associated with
lung cancer risk: 5p15, which contains the TERT gene and the
CLPTM1L gene [15–19]; 6p22.1, encompassing the MHC region
[3,15]; 6p21.33 which includes a region where the MSH5 gene
(rs3131379) resides [3,15,19]; and 6q23-25 locus harboring the
RGS17 gene [20–22].
To replicate and extend the association identified by the
GWASs in lung cancer, we chose a series of markers from the
loci 5p12.3-15.33, 6p21.33-22.1, 6q23-27 and 15q25.1, and
examined their association with other smoking related neo-
plasms. A total of 874 lung, 418 laryngeal, 450 bladder cancer
patients were sex and age matched with controls and assayed
for 14 SNPs that are located in the four regions of interest
(Table 1).
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Out of 14 SNPs genotyped, one (rs17374971) was excluded
from further analysis in all groups due to a statistically significant
deviation from Hardy-Weinberg equilibrium.
Two SNPs on chromosome 15q25 (rs16969968 and rs8034191)
were strongly associated with lung cancer (p,0.0001, p=0.0002,
respectively, Table 2) and were in strong linkage disequilibrium
(D9=0.958, r
2=0.91). Due to the high LD between rs16969968
and rs8034191, only rs16969968 will be discussed further. The
odds ratio (OR) and 95% confidence interval (95% CI) for being
heterozygous for rs16969968 when adjusted for smoking status
was 1.68 (95% CI: 1.31–2.14) and when homozygous was 1.89
(95% CI: 1.32–2.70); when incorporated into the log by additive
genetic effects model the OR was 1.45 (95% CI: 1.23–1.72).
Although we observed the strongest association of rs16969968 and
rs8034191 with the squamous cell carcinoma subtype of lung
cancer (adjusted OR=1.4 and 1.3; p=0.002 and 0.017,
Table 1. Short Nucleotide Polymorphisms (SNPs) analysed in the study.
region rs# gene name localization Reference Allele Rare Allel
5p15.33 rs2736100 telomerase reverse transcriptase (TERT) intronic T G
rs2736098 telomerase reverse transcriptase (TERT) A [Ala] ) A [Ala] G A
rs402710 CLPTM1-like (CLPTM1L) intronic C** T
5p14 rs17374971* not located in gene ---- T C
5q12.3 rs1387630 not located in gene ---- T C
6p22.1 rs4324798 not located in gene ---- G A
6p21.3 rs3131379 mutS homolog 5 (E. coli) (MSH5) intronic C T
6q23 rs1545092 not located in gene ---- T C
6q24.2 rs4286803 not located in gene ---- T C
6q24.3 rs1007475 not located in gene ---- A C
6q25 rs671330 not located in gene ---- G A
6q27 rs7452888 not located in gene ---- A G
15q25 rs8034191 aminoglycoside phosphotransferase domain
containing 1 (AGPHD1)
intronic T C
rs16969968 cholinergic receptor, nicotinic, alpha 5 (CHRNA5) D [Asp] ) N [Asn] G A
*not in Hardy Weinberg Equilibrium in one of control groups, excluded from further analysis.
**Note that in other studies minor allele (T) was the reference allele.
doi:10.1371/journal.pone.0025057.t001
Table 2. Risk estimates for rs16969968, rs803419 and rs402710 in lung cancer group.
Lung cancer unadjusted results results adjusted for smoking status
rs# Cases Controls OR p-value
95% Conf.
Interval OR p-value
95% Conf.
Interval
rs16969968 allel G 993 (59,0%) 1115 (66,3%) 1,0 — — — — — — —
A 691 (41,0%) 567 (33,7%) 1,38 ,0,0001 1,20 1,59 1,45 ,0,0001 1,23 1,72
genotype GG 280 (33,3%) 373 (44,4%) 1 — — — — — — —
GA 433 (51,4%) 369 (43,9%) 1,56 ,0,0001 1,27 1,92 1,68 ,0,0001 1,31 2,14
AA 129 (15,3%) 99 (11,8%) 1,74 0,0004 1,28 2,35 1,89 0,0005 1,32 2,70
rs8034191 allel T 991 (59,5%) 1097 (66,0%) 1,0 — — — — — — —
C 675 (40,5%) 565 (34,0%) 1,33 0,0002 1,15 1,53 1,35 0,0005 1,14 1,59
genotype TT 286 (34,3%) 368 (44,3%) 1,00 — — — — — — —
TC 419 (50,3%) 361 (43,4%) 1,49 0,0002 1,21 1,84 1,56 0,0004 1,22 2,00
CC 128 (15,4%) 102 (12,3%) 1,61 0,0018 1,19 2,19 1,63 0,0076 1,14 2,33
rs402710 allel C* 1153 (68,0%) 1071 (63,4%) 1,0 — — — — — — —
T 543 (32,0%) 619 (36,6%) 0,82 0,005 0,71 0,94 0,77 0,0020 0,66 0,91
genotype CC 398 (46,9%) 342 (40,5%) 1,00 — — — — — — —
CT 357 (42,1%) 387 (45,8%) 0,79 0,026 0,65 0,97 0,75 0,021 0,59 0,96
TT 93 (11,0%) 116 (13,7%) 0,69 0,018 0,51 0,94 0,61 0,007 0,43 0,87
*Note that in other studies minor allele (T) was the reference allele.
doi:10.1371/journal.pone.0025057.t002
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carcinoma subtype (adjusted OR=1.5, 1.4; p=0.017, 0.025) and
a tendency towards an association with the adenocarcinoma
subtype were observed (Table S1). No association between
rs16969968 and rs8034191 with the age of lung cancer diagnosis,
sex or smoking status could be identified (data not shown). Neither
of these SNPs was associated with bladder or laryngeal cancer risk
(Table S2 and S3). In a combined analysis of all control groups,
the frequency of rs16969968 and rs8034191 was similar in the
ever smokers compared to the never smokers group (adjusted for
age and sex OR=0.96, 0.97; p=0.74, p=0.8, respectively).
The association with lung cancer was also observed for the
rs402710 SNP located on chromosome 5p15.33. This SNP, was in
linkage disequilibrium with rs2736098 (D9=0.89; r
2=0.129) but
not with rs2736100 (D9=0.181; r
2=0.014). The adjusted OR for
carrying rare allele (T) of rs402710 was 0.77 (95%CI 0.66–0.91;
p=0.002). Both heterozygotes (CT) and rare homozygotes (TT)
were less frequent in the lung cancer group compared to matched
controls (adjusted OR=0.75, 0.61; p=0.021, 0.007, respectively)
(Table 2). Furthermore, an association of rs402710 with lung
squamous cell carcinoma and adenocarcioma subtypes was
observed (adjusted OR=0.69, 0.75; p=0.001, 0.033, respectively)
(Table S1). Similar to the observations related to the SNPs on
chromosome 15q25.1, no statistically significant difference was
detected when the lung cancer cases were stratified by sex, age of
diagnosis and smoking status (data not shown). In a combined
analysis of all control groups, rs402710 was not associated with
smoking status (OR adjusted for sex and age of diagnosis=1.03;
p=0.66).
Initially another association of lung cancer and rs3131379
(unadjusted OR=1.47, p=0.003) was observed, but after
adjustment for smoking status it became statistically insignificant
(Table S2 and S3). No associations of lung cancer with the
remaining 10 SNPs genotyped were observed in this study (Table
S2 and S3).
Analysis of 13 polymorphic markers among laryngeal and
bladder cases revealed that none of them were associated with
these cancer types (Table S2 and S3).
Retrospective power calculations were performed with Minor
Allele Frequencies (MAF) ranging from 0.06–0.48 to ensure that
the studied was sufficiently powered to identify any associations.
This study had 80% power at an alpha level=0.05 to detect
minimum odds ratios in the range of 1.3–1.5 for lung cancer, 1.5–
1.8 for bladder cancer and laryngeal cancer. The detection limit
increased to 1.4–1.7 (lung cancer) and 1.7–2.1 (bladder and
laryngeal cancer) with Bonferroni correction (alpha lev-
el=0.0038).
Discussion
This replication study demonstrated that SNPs in the
chromosome 15q25.1 (rs16969968 and rs8034191) and 5p15
(rs402710) are associated with lung cancer in the Polish population
thereby replicating previous findings [3–9,15–19]. It did not,
however, confirm any association between SNPs located in
15q25.1 and 5p15 region with bladder and laryngeal cancer.
The locus on chromosome 15q25.1 contains three genes that
encode nicotinic acetylcholine receptor (nAChR) subunits
(CHRNA3, CHRNA5, CHRNB4) whose involvement in tobacco
addiction was suggested from studies conducted on larger lung
cancer populations [5,10–12]. The region of association contains
the non-synonymous CHRNA5 SNP, rs16969968, which intro-
duces a substitution of aspartic acid (D) for asparagine (N) at
amino acid position 398 (D398N) of the CHRNA5 protein (a5
nAChR subunit). The a5 nAChR subunit is located in the
cytoplasmic loop between the transmembrane domains and is not
involved in receptor binding. The region of the CHRNA5 protein
where the aspartic acid substitution at position 398 occurs is highly
conserved across vertebrate species, suggesting that changes at this
position are very likely to be of functional significance. In vitro
studies indicate that aspargine at postion 398 of the a5 nAChR
subunit decreases cholinergic receptor function [13]. The nicotinic
receptors containing a5 are found in dopaminergic and GABAer-
gic neurons in the striatum and ventral tegmental area, a region of
the brain implicated in the reward pathway [13,23]. Individuals
who harbour the variant of CHRNA5 (which decreases cholin-
ergic receptor activity) may have an increased risk of nicotine
dependence as higher levels of nicotine are required to achieve
similar activation of the dopaminergic pathway [13]. Once
exposed to smoking, heterozygotes and rare homozygotes of
rs16969968 have respectively a 1.3-fold and almost 2-fold
increased risk of developing nicotine dependence [24]. Indepen-
dent observations confirmed the association of SNPs in this region
with the risk of tobacco related neoplasms like lung, bladder and
upper aeordigestive tract cancers (UADT) [3–9,25–27]. In support
of these findings other studies have shown that this locus is
implicated in the risk of chronic obstructive pulmonary disease
(COPD) and peripheral arterial disease, both of which have been
associated with smoking [5,28]. Taken together these observations
raise the question as to whether the 15q25.1 region is associated
with a direct effect on smoking related diseases or can they be
explained solely by a genetic influence on smoking addiction.
Additional studies conducted on different populations supported
the association of the 15q25.1 locus with lung cancer in never
smokers providing evidence of a direct role of this locus in disease
development [3,6]. In support of this, it has been shown that
pulmonary neuroendocrine cells, alveolar epithelial cells, pulmo-
nary neuroendocrine cells and lung cancer cell lines, express
nicotine receptors, which bind substances of carcinogenic potential
that include N9-nitrosonornicotine and nitrosamines. Thus car-
cinogens may promote neoplastic transformation by stimulating
tumor growth and angiogenesis [29,30]. Moreover, the results of a
recently conducted study on CHRNA5 activity modulation in
bronchial cells and in lung cancer cell lines suggested a potential
influence of CHRNA5 on cell adhesion as well as cell motility and
the regulation of p63, a homologous protein to the tumour
suppressor p53 [31]. Studies in large populations of mixed
ethnicity showed that this locus is implicated in all histopathologic
subtypes of lung cancer, in the current study we also replicated this
association in the Polish population, although our analysis of risk
alleles among the adenocarcinoma subtype cases showed only a
weak tendency towards an association (Table S1) [3–9]. We were
unable to show any association between SNPs in the 15q25 region
and smoking status among controls, whereas other larger studies
analyzing only nicotine dependence and concerning different
measures of smoking exposure, clearly proved this association [10–
13]. Our results were based on smaller numbers of never smoking
lung cancer patients and we therefore lacked any power to detect
this association. Our findings were, nevertheless, in agreement
with a large replication study conducted within the International
Lung Cancer Consortium using 11 645 lung cancer case patients
and 14 954 control subjects, where no association of rs16969968,
rs8034191 with lung cancer among never smokers was observed
[9]. Adding to this, a recently published meta analysis of 5
previous studies on never smoking lung cancer patients found no
association between 15q25 and lung cancer risk [32]. This puts
into question the pleiotropic notion of the 15q25 region and
suggests a more indirect effect on lung cancer risk.
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demonstrated in a case-control study of patients from Los Angeles
County, USA and Shanghai, China. In this study rs8034191 was
associated with 1.26-fold increased risk of bladder cancer among
Non-Hispanic Whites, although the authors could not replicate the
association in the Chinese population because the rare allele
frequency was too low [25]. In contrast, our data and that from a
study of 790 ever smoking bladder and renal cancer cases of
Caucasian origin indicated no association between bladder cancer
and the 15q25 region [33].
The region on chromosome 5p15.33 contains two genes,
CLPTM1L - cleft lip and palate transmembrane 1 like gene and
TERT - human telomerase reverse transcriptase gene. The TERT
enzyme is a protein component of telomerase, a ribonucleoprotein
polymerase that regenerates telomere ends by the addition of
nucleotide repeat sequences. The RNA component of telomerase
serves as a template for the telomere repeat. Telomerase plays a
crucial role in securing chromosome stability and preventing
normal cells becoming malignant. The coding region of TERT is
highly conserved between species [34]. Mutations in the coding
sequence of this gene are rare and have been associated with
dyskeratosis congenita, idiopathic pulmonary fibrosis and an
increased risk of some cancers [35,36].
The second gene in 5p15.33 is CLPTM1L, which is implicated
in the susceptibility to cleft palate. This gene is expressed in
various tissues, including lung tissue and overexpressed in
cisplatin-resistant ovarian cancer cell lines, where its role in the
induction of apoptosis in cisplatin-sensitive cells has been
demonstrated [37]. Some authors suggest that on the basis of
these observations CLPTM1L could be associated with apoptosis
induction in lung cells after exposure to genotoxic agents such as
tobacco carcinogens [16].
In this study we have investigated two SNPs (rs2736100,
rs2736098) that are situated in the region of TERT and in the
region of CLPTM1L (rs402710). Currently, there is no evidence to
suggest that any of those SNPs have a functional role or is a disease
causative allele. The region 5p15.33 has been clearly associated
with lung cancer [15–19]. In this study we replicated the
association of rs402710 with lung cancer risk in the Polish
population, but were unable to show an association of two other
SNPs, one of which (rs2736100) was suggested to be an
independent risk factor for lung cancer [16]. Stratification of our
data by histopathological subtype revealed that the strongest
association was observed among squamous cell carcinoma patients
and a weaker association for the adenocarcinoma subtype, which
is in contrast to results obtained from a GWAS, where the reverse
relationship was observed [17,18]. The 5p15.33 region was
associated with bladder cancer in a study conducted by deCODE
Genetics on a European population consisting of 4,147 cancer
cases from 10 countries or regions [38]. In this large study
rs401681 and rs2736098 were associated with an increased risk of
bladder cancer (OR=1.12, 1.16, p=5.7610
25, 1.3610
24,
5.7610
25, respectively). A study conducted on Non-Hispanic
Whites from Los Angeles county, USA and a Chinese population
showed a statistically significant association of bladder cancer with
rs2736100 in both ethnic groups [25]. In our dataset we could not
show the association of the three SNPs in the 5p15.33 region,
probably due to population differences, which was also seen in the
study by deCODE Genetics, where the rs2736098 association
when stratified by country or region, reached a p value#0.05 in
only four of the contributing countries and regions [38].
A retrospective power analysis performed in our study suggested
that one of the possible reasons we could not replicated the
findings previously reported for bladder and laryngeal cancer
groups could be due to the small sample size of these groups in our
study. This problem could be addressed by increasing the case to
control ratio from 1:1 to 1:3. In this study we were unable to
match cases and controls with higher ratios due to not being able
to recruit more controls that adhered to our matching criteria.
In summary this study has further confirmed the GWAS finding
that the regions 15q25.1 and 5p15.33 contribute to lung cancer
risk, but failed to show an association of these loci with bladder
and laryngeal cancer in the Polish population.
Materials and Methods
Between the years 2000 and 2007 a total of 1742 consecutively
collected cancer patients from clinical hospitals in Szczecin,
Poland were included in this study. The study comprised 874 cases
of lung cancer, 450 patients diagnosed with bladder cancer and
418 laryngeal cancer patients. All cases were histologically or
cytologically confirmed. Patients were invited to participate in this
study when they attended an outpatient oncology clinic in their
respective regional hospitals or the International Hereditary
Cancer Center (IHCC) in Szczecin. The patient’s participation
rate exceeded 80%. Data on smoking status was available from
91% of all cancer patients, collected at the time of registration. For
those patients where smoking status was not collected at the time
of registration it was acquired either at follow-up visits or by
personal communication (telephone, letter). Smoking status was
categorized into two categories: never and ever smokers.
The control population consisted of 1061 healthy adult patients
who had visited their family doctors located in the city of Szczecin
or surrounding counties. The participation rates for the control
population exceeded 71%. Cases and Controls were then
randomly matched by year of birth (+/23 years) and sex,
resulting in 874, 450, 418 pairs with lung, bladder and laryngeal
cancer cases, respectively. Data on smoking status was available
from 83% of all controls. The characteristics of cases and control
groups are presented in the Table 3.
The study was approved by Ethics Committee of the
Pomeranian Medical University of Szczecin. All individuals
included in this study were only enrolled after providing written
informed consent to participate.
The DNA for analysis was extracted from peripheral blood
lymphocytes of individuals using the non-enzymatic, rapid salting-
out method without modification as described previously [39].
The genotyping analysis of 14 SNP was performed using the
59exonuclease assay (TaqMan, Applied Biosystems, Foster City,
CA, U.S.A) at the International Agency for Research on Cancer.
DNA samples from cancer and control cases were randomly
allotted assay numbers during the genotyping process in order to
avoid any genotyping bias; laboratory personnel were blinded to
case/control status. 7% of the total number of subjects in this study
(derived from both cases and controls) were randomly selected to
be re-genotyped for each SNP to control for the reproducibility of
the genotyping assays. Internal duplicate concordance was
.99.9% and genotyping success rate was .91%. Out of 14
analysed SNPs, the genotype distributions of 13 SNPs did not
deviate from Hardy-Weinberg Equilibrium (HWE) in any group of
matched controls. One SNP (rs17374971) that had significant
deviation from HWE was excluded from further analysis in all
groups. Each of the SNPs was analysed individually per allele
(under the log-additive model) and per genotype by calculating
odds ratio (OR), 95% confidence interval (95% CI), p-values using
a logistic regression model. OR adjustment was performed by
incorporating smoking status as an additional parameter in logistic
regression model. Patients with missing data on smoking status
Smoking Related Cancers in the Polish Population
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all SNPs were assigned according to Single Nucleotide Polymor-
phism database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP)
[40]. All calculations were performed using the major allele of
each SNP as the reference (Table 1). Bonferroni correction was
used to adjust for multiple testing such that all results that obtained
a p value#0,0038 were considered significant. LD (D9 and r
2) was
calculated using haploview [41]. A retrospective power analysis
was performed using Power for Genetic Association Version 2.0
software with the alpha level set at 0.05 and 0.0038 under co-
dominant model with two degrees of freedom [42].
Supporting Information
Table S1 Risk estimates per allele by histopathology for
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